You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

cMET negative NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (Toripalimab, Cryoablation)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 7, 2023

NSCLC, Other Solid Tumors Trial in Australia (GB263T)

Recruiting
  • NSCLC
  • Other Solid Tumors
  • GB263T
  • Saint Leonards, New South Wales, Australia
  • +3 more
Aug 3, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Significance of MRD After Surgery in Driver Gene-positive and

Enrolling by invitation
  • NSCLC MRD ctDNA
    • Shenzhen, China
      ShenzhenPH
    Jun 30, 2022

    ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced

    Completed
    • NSCLC
    • Immune checkpoint inhibitors plus angiogenesis inhibitors
    • Immune checkpoint inhibitors without angiogenesis inhibitors
    • Suzhou, Jiangsu, China
      The Affiliated Suzhou Hospital of Nanjing Medical University
    Jan 17, 2023

    Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

    Recruiting
    • Triple Negative Breast Cancer
    • +14 more
    • LYL797
    • Scottsdale, Arizona
    • +10 more
    Jan 30, 2023

    NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

    Not yet recruiting
    • Non-small Cell Lung Cancer Stage II
    • +3 more
    • Serplulimab combined with bevacizumab and first-line chemotherapy
    • Guangzhou, Guangdong, China
      Likun Chen
    Apr 10, 2023

    ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • NGS and ctDNA-MRD detection
    • Changsha, Hunan, China
      Department of Thoracic Surgery, Second Xiangya Hospital of Centr
    Apr 18, 2023

    Metastatic NSCLC, Metastatic Triple-negative Breast Cancer Trial in Houston (biological, drug, radiation)

    Active, not recruiting
    Has Results
    • Metastatic Non-small Cell Lung Cancer
    • Metastatic Triple-negative Breast Cancer
    • ADV/HSV-tk
    • +3 more
    • Houston, Texas
      Houston Methodist Cancer Center
    Dec 28, 2022

    Resectable Stage II-IIIB Driver Gene-negative Non-small Cell

    Not yet recruiting
    • NSCLC
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Aug 6, 2023

      Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,

      Not yet recruiting
      • Lung Cancer
      • +3 more
      • Kansas City, Kansas
      • +3 more
      May 12, 2023

      NSCLC Trial in Wuhan (Apatinib)

      Enrolling by invitation
      • NSCLC
      • Wuhan, Hubei, China
        Hubei Cancer hospital
      Feb 4, 2022

      Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

      Active, not recruiting
      • Non-squamous Non-small-cell Lung Cancer
      • Brain Metastases
      • Guangzhou, Guangzhou, China
        Li-Kun Chen
      Nov 13, 2022

      Non Small Cell Lung Cancer, Endostatin Trial in Guangzhou (Endostatin)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Endostatin
      • Guangzhou, Guangdong, China
        Affiliated Cancer Hospital and Institute of Guangzhou Medical Un
      Jul 4, 2022

      NSCLC Stage IV, Oligometastasis Trial in Xi'an (Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment

      Recruiting
      • NSCLC Stage IV
      • Oligometastasis
      • Toripalimab in Combination With Platinum-based Chemotherapy
      • +2 more
      • Xi'an, Shaanxi, China
        The Fourth Military Medical University Tangdu Hospital
      Sep 15, 2021

      NSCLC, Stage IIIA, EGF-R Negative NSCLC, ALK Negative NSCLC Trial in Shanghai (PD-1 and chemo)

      Recruiting
      • NSCLC, Stage IIIA
      • +2 more
      • PD-1 and chemotherapy
      • Shanghai, Shanghai, China
        Shanghai General Hospital
      Dec 14, 2021

      SBRT, NSCLC, Non-metastatic Trial in United States (GC4711, Placebo)

      Recruiting
      • SBRT
      • +2 more
      • Gilbert, Arizona
      • +11 more
      Aug 9, 2022

      Solid Tumor, Advanced Cancer, Metastatic Cancer Trial in Tampa, Durham (MEM-288 Intratumoral Injection)

      Recruiting
      • Solid Tumor
      • +9 more
      • MEM-288 Intratumoral Injection
      • Tampa, Florida
      • +1 more
      Jun 27, 2022

      NSCLC Trial in Worldwide (INC280 (capmatinib))

      Active, not recruiting
      • Carcinoma, Non-Small-Cell Lung
      • INC280 (capmatinib)
      • Long Beach, California
      • +95 more
      Dec 29, 2022

      Non Small Cell Lung Cancer Trial (Jinfukang oral liquid, Platinum-based doublet chemo)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Jinfukang oral liquid
      • Platinum-based doublet chemotherapy
      • (no location specified)
      Oct 17, 2021

      NSCLC Trial in Wuhan (Toripalimab, Anlotinib, SBRT 7Gy??5 QD)

      Recruiting
      • NSCLC
      • Wuhan, Hubei, China
        Hubei Cancer Hospital
      Nov 29, 2021

      Advanced Cancer, Advanced Malignancies, Bladder Cancer Trial (AB598, Zimberelimab, Carboplatin)

      Not yet recruiting
      • Advanced Cancer
      • +11 more
      • (no location specified)
      May 26, 2023

      Non-squamous NSCLC Trial in Worldwide (Tusamitamab ravtansine)

      Recruiting
      • Non-squamous Non-small Cell Lung Cancer
      • Tusamitamab ravtansine
      • Edegem, Belgium
      • +18 more
      Aug 3, 2022

      Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III Trial in Worldwide (Durvalumab Injection)

      Recruiting
      • Cancer
      • +4 more
      • Durvalumab Injection
      • Tallinn, Estonia
      • +9 more
      Dec 1, 2021

      NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

      Terminated
      • Carcinoma, Non-Small-Cell Lung
      • Kashiwa, Chiba, Japan
      • +3 more
      Jan 31, 2023